Bracco Imaging, Marillion partner for new cancer treatment

TriMed Staff | | Health Imaging | Diagnostic Imaging
Marillion Pharmaceuticals and Bracco Imaging, part of the Bracco Group, have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco’s 177Lu-AMBA for the treatment of hormone-resistant prostate and metastatic breast cancers.
 
Bracco’s 177Lu-AMBA is a targeted radiotherapeutic that utilizes an innovative receptor-based technology to home in on tumor cells and spare normal tissues. Early clinical trials have shown that these metastases may also be effectively targeted by 177Lu-AMBA, according to Zahed Subhan, MD, CEO of Marillion, based in Exton, Pa.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.